These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16846405)

  • 1. Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: a less commonly perceived therapeutic perspective in clinical practice.
    Varughese GI; Scarpello JH
    Int J Clin Pract; 2006 Jul; 60(7):884-8. PubMed ID: 16846405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: another focus.
    Tahrani AA
    Int J Clin Pract; 2006 Nov; 60(11):1515; author reply 1515-6. PubMed ID: 17073848
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapies for diabetic dyslipidaemia.
    Bell DS; Al Badarin F; O'Keefe JH
    Diabetes Obes Metab; 2011 Apr; 13(4):313-25. PubMed ID: 21205114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.
    Costa J; Borges M; David C; Vaz Carneiro A
    BMJ; 2006 May; 332(7550):1115-24. PubMed ID: 16585050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidaemia in the elderly: to treat or not to treat?
    Katsiki N; Kolovou G; Perez-Martinez P; Mikhailidis DP
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):259-278. PubMed ID: 29303009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes.
    Standl E
    Diab Vasc Dis Res; 2013 Mar; 10(2):99-114. PubMed ID: 22718811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapy of diabetic dyslipidemia: do the statins suffice?
    Mooradian AD
    Am J Ther; 2015; 22(1):87-8. PubMed ID: 23728161
    [No Abstract]   [Full Text] [Related]  

  • 13. Dyslipidaemia in perspective.
    Kastelein JJP
    Lancet; 2014 Aug; 384(9943):566-568. PubMed ID: 25131971
    [No Abstract]   [Full Text] [Related]  

  • 14. Managing dyslipidaemia for the primary prevention of cardiovascular disease.
    Ryan A; Heath S; Cook P
    BMJ; 2018 Mar; 360():k946. PubMed ID: 29572251
    [No Abstract]   [Full Text] [Related]  

  • 15. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.
    Chan DC; Wong AT; Yamashita S; Watts GF
    Atherosclerosis; 2012 Apr; 221(2):484-9. PubMed ID: 22341868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidemia in youth with diabetes: to treat or not to treat?
    Maahs DM; Wadwa RP; Bishop F; Daniels SR; Rewers M; Klingensmith GJ
    J Pediatr; 2008 Oct; 153(4):458-65. PubMed ID: 18847618
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lipid management--treatment goal and strategy].
    Koshiyama H
    Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.
    Watts GF; Karpe F
    Heart; 2011 Mar; 97(5):350-6. PubMed ID: 21296781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
    Keating GM; Croom KF
    Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidemia vs hyperglycemia.
    Feeman WE
    Prev Cardiol; 2007; 10(2):112. PubMed ID: 17392624
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.